Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CER 001

X
Drug Profile

CER 001

Alternative Names: CER-001; Cerenis HDL; Recombinant Human Apolipoprotein A-I; Recombinant Human Apolipoprotein A-I/Phospholipids complex

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerenis Therapeutics
  • Developer ABIONYX Pharma; Academic Medical Center
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Cardiovascular therapies; Eye disorder therapies; Phospholipids; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Apolipoprotein A-I replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency; Hypoalphalipoproteinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypoalphalipoproteinaemia
  • Phase II Acute coronary syndromes; Acute kidney injury; Atherosclerosis
  • Clinical Phase Unknown COVID 2019 infections; Lecithin acyltransferase deficiency
  • Preclinical Uveitis
  • No development reported Lipid metabolism disorders

Most Recent Events

  • 14 Mar 2024 ABIONYX Pharma plans a clinical trial for Eye disorders in
  • 27 Nov 2023 Interim pharmacodynamics data from a preclinical study in acute kidney disease released by ABIONYX
  • 21 Nov 2023 Updated pharmacodynamics data from a preclinical trial in Uveitis released by ABIONYX Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top